An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 02 Nov 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 07 Jan 2015 Planned End Date changed from 1 Jun 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.